Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valethamate is a small molecule anticholinergic and antispasmodic agent used to manage smooth muscle spasms, including those associated with dysmenorrhea, gastrointestinal tract cramping, postoperative pain, tenesmus, urinary and biliary colic. It is commonly used to hasten cervical dilatation during labor. The drug acts as a competitive inhibitor of acetylcholine at muscarinic receptors (antimuscarinic action), blocking cholinergic transmission in ganglia and directly relaxing smooth muscles of the cervix and intestine. This leads to reduced spasms but can also cause typical anticholinergic side effects such as tachycardia, dry mouth, blurred vision, constipation, urinary retention, flushing, photophobia due to mydriasis[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valethamate.